Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3

Status

Unknown 10Not yet recruiting 6Recruiting 5Completed 5Terminated 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 3BRCA-Mutated Breast Carcinoma 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × famitinib × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Fudan University

Phase 2 Recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Fudan University

Phase 2 Recruiting
160 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06516289 2024-12-12

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Fudan University

Phase 2 Recruiting
130 enrolled
Breast

BRCA-Mutated Breast Carcinoma

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Fudan University

Phase 2 Recruiting
620 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡